When the cut-off value for galectin-3 for predicting exacerbations in COPD patients was set at 2.19 ng/mL, sensitivity and specificity were 77% and 58%, respectively (AUC: 0.755, 95% Cl: 0.611–0.866, p = 0.001) (Figure 2). This evidence concerns the gene LGALS3 and chronic obstructive pulmonary disease.